A Phase 2 interventional study of Combination [RSVpreF+BNTb162b2] and Bivalent BNT162b2 (original/Omi BA.4/BA.5) in Healthy Participants, sponsored by Pfizer. Completed at 37 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-18.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.
Among the 69 studies in COVID-19 by Pfizer, this one is the 5th largest by enrollment of the 41 interventional ones that give a count, is one of 12 that started in 2023, is one of 7 in phase 2, and was the 43rd registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 16 more countries
Ages 12+
Pfizer · Sites in Korea, Republic of
Ages 19+
Pfizer · Sites in United States, Bulgaria, Japan and 4 more countries
Ages 0–17
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 11 · Phase 3 8 · Phase 4 1
First in 2020; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,142 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 20 across the 41 interventional studies, 2,038 across the 28 observational. Of the 53 that completed or were terminated, 39 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
5 of the studies in COVID-19 by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT06613984PfizerKorean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) | 2026-12-30 |
| NCT05032976PfizerKorea Comirnaty Post-marketing Surveillance | 2027-01-24 |
| NCT05160636PfizerA Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza | 2027-01-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in COVID-19 by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone. A combined vaccine will help to reduce the number of vaccinations given when trying to prevent respiratory infections.
This study is seeking participants who:
Participants will be involved in this study for 6 months. During this time, participants will have 2 study visits at the study clinic and a 6-month telephone contact.
Substudy A Inclusion Criteria:
Substudy A Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination \[RSVpreF+BNT162b2\] + Quadrivalent influenza vaccine (QIV)
Biological: Combination [RSVpreF+BNTb162b2] · Biological: QIV
Combination \[RSVpreF+BNT162b2\] + placebo
Biological: Combination [RSVpreF+BNTb162b2] · Biological: Normal Saline Placebo
BNT162b2 + placebo
Biological: Bivalent BNT162b2 (original/Omi BA.4/BA.5) · Biological: Normal Saline Placebo
RSVpreF + placebo
Biological: RSVpreF · Biological: Normal Saline Placebo
QIV + placebo
Biological: QIV · Biological: Normal Saline Placebo
Coadministration RSVpreF + bivalent BNT162b2 + placebo
Biological: Bivalent BNT162b2 (original/Omi BA.4/BA.5) · Biological: RSVpreF · Biological: Normal Saline Placebo
Coadministration RSVpreF + bivalent BNT162b2 + QIV
Biological: Bivalent BNT162b2 (original/Omi BA.4/BA.5) · Biological: RSVpreF · Biological: QIV
Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection
Bivalent BNT162b2 given as an intramuscular injection
RSVpreF given as an intramuscular injection
Licensed QIV given as an intramuscular injection
Normal saline (0.9% sodium chloride solution for injection)
Percentage of Participants With Local Reactions Within 7 Days After Vaccination
Local reactions included pain, redness and swelling at the injection site, recorded by participants in an electronic diary (e-diary). Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 centimeter (cm) and graded as mild: 2.5 cm to 5.0 cm; moderate: greater than (\>) 5.0 cm to 10.0 cm; severe: \> 10 cm.
Time frame: Day 1 to Day 7 after Vaccination on Day 1
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Systemic events included fever, fatigue, headache, vomiting, diarrhea, chills, new/worsened muscle pain and joint pain. These were recorded by participants in an e-diary. Fever was defined as oral temperature greater than or equal to (\>=) 38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting was categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea was categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h and severe: 6 or more loose stools in 24h. Headache, fatigue, chills, new/worsened muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity and severe: prevented daily routine activity.
Time frame: Day 1 to Day 7 after Vaccination on Day 1
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention were included in evaluation of this outcome measure.
Time frame: Within 1 Month after Vaccination
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.
Time frame: Within 6 Months after Vaccination
Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) of Neutralizing Titers (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) at 1 Month After Vaccination: Group 1 Versus Group 4
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV A were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV A, calculated as ratio of GMTs of Group 1 to Group 4, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for Respiratory Syncytial Virus Subgroup B (RSV B) at 1 Month After Vaccination: Group 1 Versus Group 4
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV B were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV B, calculated as ratio of GMTs of Group 1 to Group 4, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5 at 1 Month After Vaccination: Group 1 Versus Group 3
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 Omicron BA.4/BA.5 were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5, calculated as ratio of GMTs of Group 1 to Group 3, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for SARS-CoV-2 Reference Strain at 1 Month After Vaccination: Group 1 Versus Group 3
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 reference strain were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 reference strain calculated as ratio of GMTs of Group 1 to Group 3, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of the Strain-Specific Hemagglutination Inhibition (HAI) Titers (H1N1 A/Victoria) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (H1N1 A/Victoria) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (H1N1 A/Victoria), calculated as ratio of GMTs of Group 1 to Group 5, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of the Strain-Specific HAI Titers (H3N2 A/Darwin) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (H3N2 A/Darwin) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (H3N2 A/Darwin), calculated as ratio of GMTs of Group 1 to Group 5, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of the Strain-Specific HAI Titers (B/Austria) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (B/Austria) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (B/Austria), calculated as ratio of GMTs of Group 1 to Group 5, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of the Strain-Specific HAI Titers (B/Phuket) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (B/Phuket) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (B/Phuket), calculated as ratio of GMTs of Group 1 to Group 5, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for RSV A at 1 Month After Vaccination: Group 2 Versus Group 4
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV A were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV A, calculated as ratio of GMTs of Group 2 to Group 4, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for RSV B at 1 Month After Vaccination: Group 2 Versus Group 4
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV B were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV B, calculated as ratio of GMTs of Group 2 to Group 4, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5 at 1 Month After Vaccination: Group 2 Versus Group 3
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 Omicron BA.4/BA.5 were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5, calculated as ratio of GMTs of Group 2 to Group 3, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for SARS-CoV-2 Reference Strain at 1 Month After Vaccination: Group 2 Versus Group 3
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 reference strain were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 reference strain calculated as ratio of GMTs of Group 2 to Group 3, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for RSV A at 1 Month After Vaccination: Group 7 Versus Group 4
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV A were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV A, calculated as ratio of GMTs of Group 7 to Group 4, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for RSV B at 1 Month After Vaccination: Group 7 Versus Group 4
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV B were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV B, calculated as ratio of GMTs of Group 7 to Group 4, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5 at 1 Month After Vaccination: Group 7 Versus Group 3
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 Omicron BA.4/BA.5 were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5, calculated as ratio of GMTs of Group 7 to Group 3, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for SARS-CoV-2 Reference Strain at 1 Month After Vaccination: Group 7 Versus Group 3
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 reference strain were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 reference strain calculated as ratio of GMTs of Group 7 to Group 3, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of the Strain-Specific HAI Titers (H1N1 A/Victoria) of QIV at 1 Month After Vaccination: Group 7 Versus Group 5
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (H1N1 A/Victoria) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (H1N1 A/Victoria), calculated as ratio of GMTs of Group 7 to Group 5, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of the Strain-Specific HAI Titers (H3N2 A/Darwin) of QIV at 1 Month After Vaccination: Group 7 Versus Group 5
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (H3N2 A/Darwin) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (H3N2 A/Darwin), calculated as ratio of GMTs of Group 7 to Group 5, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of the Strain-Specific HAI Titers (B/Austria) of QIV at 1 Month After Vaccination: Group 7 Versus Group 5
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (B/Austria) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (B/Austria), calculated as ratio of GMTs of Group 7 to Group 5, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of the Strain-Specific HAI Titers (B/Phuket) of QIV at 1 Month After Vaccination: Group 7 Versus Group 5
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (B/Phuket) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (B/Phuket), calculated as ratio of GMTs of Group 7 to Group 5, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for RSV A at 1 Month After Vaccination: Group 6 Versus Group 4
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV A were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV A, calculated as ratio of GMTs of Group 6 to Group 4, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for RSV B at 1 Month After Vaccination: Group 6 Versus Group 4
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV B were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV B, calculated as ratio of GMTs of Group 6 to Group 4, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5 at 1 Month After Vaccination: Group 6 Versus Group 3
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 Omicron BA.4/BA.5 were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5, calculated as ratio of GMTs of Group 6 to Group 3, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
GMT and GMR of NTs for SARS-CoV-2 Reference Strain at 1 Month After Vaccination: Group 6 Versus Group 3
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 reference strain were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 reference strain calculated as ratio of GMTs of Group 6 to Group 3, was reported in the statistical analysis section.
Time frame: 1 Month after Vaccination
A total of 1142 participants were enrolled in this study, 1083 participants were randomized to receive study vaccination, out of which, 1073 participants were vaccinated.
| Milestone | Group 1: [RSVpreF + BNT162b2] + QIV | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo | Group 4: RSVpreF + Placebo | Group 5: QIV + Placebo | Group 6: RSVpreF + BNT162b2 + Placebo | Group 7: RSVpreF + BNT162b2 + QIV |
|---|---|---|---|---|---|---|---|
| Started | 155 | 154 | 152 | 155 | 151 | 158 | 158 |
| Completed | 153 | 151 | 147 | 150 | 148 | 155 | 157 |
| Not completed | 2 | 3 | 5 | 5 | 3 | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 1 | 0 | 2 | 0 |
| Withdrew: Other | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 4 | 3 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: No longer met eligibility criteria | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Local reactions included pain, redness and swelling at the injection site, recorded by participants in an electronic diary (e-diary). Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 centimeter (cm) and graded as mild: 2.5 cm to 5.0 cm; moderate: greater than (\>) 5.0 cm to 10.0 cm; severe: \> 10 cm.
| Percentage of participants | Group 1: [RSVpreF + BNT162b2] + QIV | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo | Group 4: RSVpreF + Placebo | Group 5: QIV + Placebo | Group 6: RSVpreF + BNT162b2 + Placebo | Group 7: RSVpreF + BNT162b2 + QIV |
|---|---|---|---|---|---|---|---|
| Pain at the injection site: Mild | 49.4 (41.2 to 57.5) | 45.8 (37.7 to 54.0) | 54.7 (46.3 to 62.8) | 10.5 (6.1 to 16.5) | 48.3 (40.1 to 56.6) | 45.2 (37.3 to 53.4) | 44.9 (37.0 to 53.0) |
| Pain at the injection site: Moderate | 7.8 (4.1 to 13.2) | 5.9 (2.7 to 10.9) | 7.3 (3.7 to 12.7) | 0 (0.0 to 2.4) | 3.4 (1.1 to 7.7) | 11.5 (6.9 to 17.5) | 7.6 (4.0 to 12.9) |
| Pain at the injection site: Severe | 0 (0.0 to 2.4) | 0.7 (0.0 to 3.6) | 0.7 (0.0 to 3.7) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.3) | 1.3 (0.2 to 4.5) |
| Redness: Mild | 3.2 (1.1 to 7.4) | 5.9 (2.7 to 10.9) | 5.3 (2.3 to 10.2) | 1.3 (0.2 to 4.7) | 2.0 (0.4 to 5.8) | 6.4 (3.1 to 11.4) | 5.1 (2.2 to 9.7) |
| Redness: Moderate | 4.5 (1.8 to 9.1) | 3.3 (1.1 to 7.5) | 2.0 (0.4 to 5.7) | 1.3 (0.2 to 4.7) | 2.0 (0.4 to 5.8) | 5.1 (2.2 to 9.8) | 3.2 (1.0 to 7.2) |
| Redness: Severe | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 1.3 (0.2 to 4.5) | 0.6 (0.0 to 3.5) |
| Swelling: Mild | 3.2 (1.1 to 7.4) | 6.5 (3.2 to 11.7) | 5.3 (2.3 to 10.2) | 2.0 (0.4 to 5.7) | 4.0 (1.5 to 8.6) | 7.6 (4.0 to 13.0) | 2.5 (0.7 to 6.4) |
| Swelling: Moderate | 1.9 (0.4 to 5.6) | 4.6 (1.9 to 9.2) | 4.0 (1.5 to 8.5) | 1.3 (0.2 to 4.7) | 2.0 (0.4 to 5.8) | 4.5 (1.8 to 9.0) | 4.4 (1.8 to 8.9) |
| Swelling: Severe | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0.6 (0.0 to 3.5) | 0 (0.0 to 2.3) |
Systemic events included fever, fatigue, headache, vomiting, diarrhea, chills, new/worsened muscle pain and joint pain. These were recorded by participants in an e-diary. Fever was defined as oral temperature greater than or equal to (\>=) 38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting was categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea was categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h and severe: 6 or more loose stools in 24h. Headache, fatigue, chills, new/worsened muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity and severe: prevented daily routine activity.
| Percentage of participants | Group 1: [RSVpreF + BNT162b2] + QIV | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo | Group 4: RSVpreF + Placebo | Group 5: QIV + Placebo | Group 6: RSVpreF + BNT162b2 + Placebo | Group 7: RSVpreF + BNT162b2 + QIV |
|---|---|---|---|---|---|---|---|
| Fever: Mild | 3.2 (1.1 to 7.4) | 2.0 (0.4 to 5.6) | 1.3 (0.2 to 4.7) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 1.3 (0.2 to 4.5) | 2.5 (0.7 to 6.4) |
| Fever: Moderate | 0.6 (0.0 to 3.6) | 1.3 (0.2 to 4.6) | 0 (0.0 to 2.4) | 1.3 (0.2 to 4.7) | 0 (0.0 to 2.4) | 0.6 (0.0 to 3.5) | 1.9 (0.4 to 5.4) |
| Fever: Severe | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.3) | 0 (0.0 to 2.3) |
| Fatigue: Mild | 21.4 (15.2 to 28.8) | 17.0 (11.4 to 23.9) | 18.0 (12.2 to 25.1) | 15.8 (10.4 to 22.6) | 17.4 (11.7 to 24.5) | 17.2 (11.6 to 24.0) | 20.9 (14.8 to 28.1) |
| Fatigue: Moderate | 19.5 (13.5 to 26.6) | 19.0 (13.1 to 26.1) | 16.7 (11.1 to 23.6) | 7.9 (4.1 to 13.4) | 10.7 (6.3 to 16.9) | 20.4 (14.4 to 27.5) | 24.1 (17.6 to 31.5) |
| Fatigue: Severe | 1.3 (0.2 to 4.6) | 1.3 (0.2 to 4.6) | 0.7 (0.0 to 3.7) | 0.7 (0.0 to 3.6) | 0.7 (0.0 to 3.7) | 1.3 (0.2 to 4.5) | 1.9 (0.4 to 5.4) |
| Headache: Mild | 16.2 (10.8 to 23.0) | 19.0 (13.1 to 26.1) | 14.0 (8.9 to 20.6) | 15.8 (10.4 to 22.6) | 10.1 (5.7 to 16.1) | 15.3 (10.0 to 21.9) | 11.4 (6.9 to 17.4) |
| Headache: Moderate | 5.2 (2.3 to 10.0) | 5.9 (2.7 to 10.9) | 8.7 (4.7 to 14.4) | 3.3 (1.1 to 7.5) | 2.7 (0.7 to 6.7) | 8.3 (4.5 to 13.7) | 7.0 (3.5 to 12.1) |
| Headache: Severe | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0.6 (0.0 to 3.5) | 0.6 (0.0 to 3.5) |
| Vomiting: Mild | 1.3 (0.2 to 4.6) | 0 (0.0 to 2.4) | 1.3 (0.2 to 4.7) | 2.6 (0.7 to 6.6) | 0.7 (0.0 to 3.7) | 0.6 (0.0 to 3.5) | 1.3 (0.2 to 4.5) |
| Vomiting: Moderate | 0.6 (0.0 to 3.6) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.3) | 0 (0.0 to 2.3) |
| Vomiting: Severe | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.3) | 0 (0.0 to 2.3) |
| Diarrhea: Mild | 5.8 (2.7 to 10.8) | 3.3 (1.1 to 7.5) | 4.0 (1.5 to 8.5) | 7.2 (3.7 to 12.6) | 7.4 (3.7 to 12.8) | 4.5 (1.8 to 9.0) | 10.1 (5.9 to 15.9) |
| Diarrhea: Moderate | 5.2 (2.3 to 10.0) | 0 (0.0 to 2.4) | 1.3 (0.2 to 4.7) | 2.6 (0.7 to 6.6) | 2.0 (0.4 to 5.8) | 0 (0.0 to 2.3) | 1.9 (0.4 to 5.4) |
| Diarrhea: Severe | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0.7 (0.0 to 3.6) | 0 (0.0 to 2.4) | 0 (0.0 to 2.3) | 0.6 (0.0 to 3.5) |
| Chills: Mild | 7.1 (3.6 to 12.4) | 5.9 (2.7 to 10.9) | 6.7 (3.2 to 11.9) | 2.0 (0.4 to 5.7) | 2.0 (0.4 to 5.8) | 4.5 (1.8 to 9.0) | 5.7 (2.6 to 10.5) |
| Chills: Moderate | 3.2 (1.1 to 7.4) | 2.0 (0.4 to 5.6) | 2.7 (0.7 to 6.7) | 2.0 (0.4 to 5.7) | 0 (0.0 to 2.4) | 5.1 (2.2 to 9.8) | 5.1 (2.2 to 9.7) |
| Chills: Severe | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0.6 (0.0 to 3.5) | 0 (0.0 to 2.3) |
| New or worsened muscle pain: Mild | 7.8 (4.1 to 13.2) | 5.9 (2.7 to 10.9) | 6.0 (2.8 to 11.1) | 3.9 (1.5 to 8.4) | 6.0 (2.8 to 11.2) | 8.3 (4.5 to 13.7) | 7.0 (3.5 to 12.1) |
| New or worsened muscle pain: Moderate | 5.2 (2.3 to 10.0) | 4.6 (1.9 to 9.2) | 4.7 (1.9 to 9.4) | 5.9 (2.7 to 10.9) | 4.7 (1.9 to 9.4) | 5.1 (2.2 to 9.8) | 7.6 (4.0 to 12.9) |
| New or worsened muscle pain: Severe | 0 (0.0 to 2.4) | 0.7 (0.0 to 3.6) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0.6 (0.0 to 3.5) | 0 (0.0 to 2.3) |
| New or worsened joint pain: Mild | 4.5 (1.8 to 9.1) | 4.6 (1.9 to 9.2) | 1.3 (0.2 to 4.7) | 2.0 (0.4 to 5.7) | 0.7 (0.0 to 3.7) | 4.5 (1.8 to 9.0) | 5.1 (2.2 to 9.7) |
| New or worsened joint pain: Moderate | 3.9 (1.4 to 8.3) | 2.6 (0.7 to 6.6) | 7.3 (3.7 to 12.7) | 3.9 (1.5 to 8.4) | 3.4 (1.1 to 7.7) | 5.7 (2.7 to 10.6) | 3.8 (1.4 to 8.1) |
| New or worsened joint pain: Severe | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.4) | 0 (0.0 to 2.3) | 0.6 (0.0 to 3.5) |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention were included in evaluation of this outcome measure.
| Percentage of participants | Group 1: [RSVpreF + BNT162b2] + QIV | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo | Group 4: RSVpreF + Placebo | Group 5: QIV + Placebo | Group 6: RSVpreF + BNT162b2 + Placebo | Group 7: RSVpreF + BNT162b2 + QIV |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination | 9.1 (5.1 to 14.8) | 8.5 (4.6 to 14.1) | 8.0 (4.2 to 13.6) | 7.2 (3.7 to 12.6) | 8.1 (4.2 to 13.6) | 8.9 (5.0 to 14.5) | 8.9 (4.9 to 14.4) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.
| Percentage of participants | Group 1: [RSVpreF + BNT162b2] + QIV | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo | Group 4: RSVpreF + Placebo | Group 5: QIV + Placebo | Group 6: RSVpreF + BNT162b2 + Placebo | Group 7: RSVpreF + BNT162b2 + QIV |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination | 0.6 (0.0 to 3.6) | 1.3 (0.2 to 4.6) | 2.7 (0.7 to 6.7) | 1.3 (0.2 to 4.7) | 1.3 (0.2 to 4.8) | 0.6 (0.0 to 3.5) | 1.9 (0.4 to 5.4) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV A were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV A, calculated as ratio of GMTs of Group 1 to Group 4, was reported in the statistical analysis section.
| Titer | Group 1: [RSVpreF + BNT162b2] + QIV | Group 4: RSVpreF + Placebo |
|---|---|---|
| Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) of Neutralizing Titers (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) at 1 Month After Vaccination: Group 1 Versus Group 4 | 18284 (15576.6 to 21462.6) | 18498 (15570.0 to 21975.9) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV B were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV B, calculated as ratio of GMTs of Group 1 to Group 4, was reported in the statistical analysis section.
| Titer | Group 1: [RSVpreF + BNT162b2] + QIV | Group 4: RSVpreF + Placebo |
|---|---|---|
| GMT and GMR of NTs for Respiratory Syncytial Virus Subgroup B (RSV B) at 1 Month After Vaccination: Group 1 Versus Group 4 | 15014 (12543.8 to 17971.8) | 16677 (13884.0 to 20031.4) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 Omicron BA.4/BA.5 were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5, calculated as ratio of GMTs of Group 1 to Group 3, was reported in the statistical analysis section.
| Titer | Group 1: [RSVpreF + BNT162b2] + QIV | Group 3: BNT162b2 + Placebo |
|---|---|---|
| GMT and GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5 at 1 Month After Vaccination: Group 1 Versus Group 3 | 3083 (2476.7 to 3838.1) | 3667 (2861.9 to 4697.5) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 reference strain were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 reference strain calculated as ratio of GMTs of Group 1 to Group 3, was reported in the statistical analysis section.
| Titer | Group 1: [RSVpreF + BNT162b2] + QIV | Group 3: BNT162b2 + Placebo |
|---|---|---|
| GMT and GMR of NTs for SARS-CoV-2 Reference Strain at 1 Month After Vaccination: Group 1 Versus Group 3 | 9849 (8497.6 to 11416.5) | 12439 (10185.9 to 15190.1) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (H1N1 A/Victoria) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (H1N1 A/Victoria), calculated as ratio of GMTs of Group 1 to Group 5, was reported in the statistical analysis section.
| Titer | Group 1: [RSVpreF + BNT162b2] + QIV | Group 5: QIV + Placebo |
|---|---|---|
| GMT and GMR of the Strain-Specific Hemagglutination Inhibition (HAI) Titers (H1N1 A/Victoria) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5 | 70 (56.8 to 87.3) | 67 (54.1 to 82.0) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (H3N2 A/Darwin) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (H3N2 A/Darwin), calculated as ratio of GMTs of Group 1 to Group 5, was reported in the statistical analysis section.
| Titer | Group 1: [RSVpreF + BNT162b2] + QIV | Group 5: QIV + Placebo |
|---|---|---|
| GMT and GMR of the Strain-Specific HAI Titers (H3N2 A/Darwin) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5 | 138 (117.3 to 162.3) | 122 (105.7 to 141.4) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (B/Austria) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (B/Austria), calculated as ratio of GMTs of Group 1 to Group 5, was reported in the statistical analysis section.
| Titer | Group 1: [RSVpreF + BNT162b2] + QIV | Group 5: QIV + Placebo |
|---|---|---|
| GMT and GMR of the Strain-Specific HAI Titers (B/Austria) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5 | 71 (57.5 to 88.8) | 68 (54.3 to 84.8) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (B/Phuket) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (B/Phuket), calculated as ratio of GMTs of Group 1 to Group 5, was reported in the statistical analysis section.
| Titer | Group 1: [RSVpreF + BNT162b2] + QIV | Group 5: QIV + Placebo |
|---|---|---|
| GMT and GMR of the Strain-Specific HAI Titers (B/Phuket) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5 | 30 (23.6 to 37.2) | 27 (21.5 to 33.3) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV A were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV A, calculated as ratio of GMTs of Group 2 to Group 4, was reported in the statistical analysis section.
| Titer | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 4: RSVpreF + Placebo |
|---|---|---|
| GMT and GMR of NTs for RSV A at 1 Month After Vaccination: Group 2 Versus Group 4 | 18414 (15172.8 to 22346.9) | 18498 (15570.0 to 21975.9) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV B were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV B, calculated as ratio of GMTs of Group 2 to Group 4, was reported in the statistical analysis section.
| Titer | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 4: RSVpreF + Placebo |
|---|---|---|
| GMT and GMR of NTs for RSV B at 1 Month After Vaccination: Group 2 Versus Group 4 | 18227 (14961.9 to 22204.2) | 16677 (13884.0 to 20031.4) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 Omicron BA.4/BA.5 were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5, calculated as ratio of GMTs of Group 2 to Group 3, was reported in the statistical analysis section.
| Titer | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo |
|---|---|---|
| GMT and GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5 at 1 Month After Vaccination: Group 2 Versus Group 3 | 3083 (2412.5 to 3940.4) | 3667 (2861.9 to 4697.5) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 reference strain were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 reference strain calculated as ratio of GMTs of Group 2 to Group 3, was reported in the statistical analysis section.
| Titer | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo |
|---|---|---|
| GMT and GMR of NTs for SARS-CoV-2 Reference Strain at 1 Month After Vaccination: Group 2 Versus Group 3 | 10489 (8500.2 to 12943.5) | 12439 (10185.9 to 15190.1) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV A were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV A, calculated as ratio of GMTs of Group 7 to Group 4, was reported in the statistical analysis section.
| Titer | Group 7: RSVpreF + BNT162b2 + QIV | Group 4: RSVpreF + Placebo |
|---|---|---|
| GMT and GMR of NTs for RSV A at 1 Month After Vaccination: Group 7 Versus Group 4 | 26303 (22338.8 to 30970.5) | 18498 (15570.0 to 21975.9) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV B were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV B, calculated as ratio of GMTs of Group 7 to Group 4, was reported in the statistical analysis section.
| Titer | Group 7: RSVpreF + BNT162b2 + QIV | Group 4: RSVpreF + Placebo |
|---|---|---|
| GMT and GMR of NTs for RSV B at 1 Month After Vaccination: Group 7 Versus Group 4 | 21182 (17525.4 to 25600.8) | 16677 (13884.0 to 20031.4) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 Omicron BA.4/BA.5 were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5, calculated as ratio of GMTs of Group 7 to Group 3, was reported in the statistical analysis section.
| Titer | Group 7: RSVpreF + BNT162b2 + QIV | Group 3: BNT162b2 + Placebo |
|---|---|---|
| GMT and GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5 at 1 Month After Vaccination: Group 7 Versus Group 3 | 3148 (2482.6 to 3992.0) | 3667 (2861.9 to 4697.5) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 reference strain were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 reference strain calculated as ratio of GMTs of Group 7 to Group 3, was reported in the statistical analysis section.
| Titer | Group 7: RSVpreF + BNT162b2 + QIV | Group 3: BNT162b2 + Placebo |
|---|---|---|
| GMT and GMR of NTs for SARS-CoV-2 Reference Strain at 1 Month After Vaccination: Group 7 Versus Group 3 | 12588 (10312.2 to 15365.4) | 12439 (10185.9 to 15190.1) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (H1N1 A/Victoria) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (H1N1 A/Victoria), calculated as ratio of GMTs of Group 7 to Group 5, was reported in the statistical analysis section.
| Titer | Group 7: RSVpreF + BNT162b2 + QIV | Group 5: QIV + Placebo |
|---|---|---|
| GMT and GMR of the Strain-Specific HAI Titers (H1N1 A/Victoria) of QIV at 1 Month After Vaccination: Group 7 Versus Group 5 | 166 (141.0 to 194.7) | 67 (54.1 to 82.0) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (H3N2 A/Darwin) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (H3N2 A/Darwin), calculated as ratio of GMTs of Group 7 to Group 5, was reported in the statistical analysis section.
| Titer | Group 7: RSVpreF + BNT162b2 + QIV | Group 5: QIV + Placebo |
|---|---|---|
| GMT and GMR of the Strain-Specific HAI Titers (H3N2 A/Darwin) of QIV at 1 Month After Vaccination: Group 7 Versus Group 5 | 159 (135.6 to 186.5) | 122 (105.7 to 141.4) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (B/Austria) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (B/Austria), calculated as ratio of GMTs of Group 7 to Group 5, was reported in the statistical analysis section.
| Titer | Group 7: RSVpreF + BNT162b2 + QIV | Group 5: QIV + Placebo |
|---|---|---|
| GMT and GMR of the Strain-Specific HAI Titers (B/Austria) of QIV at 1 Month After Vaccination: Group 7 Versus Group 5 | 107 (85.8 to 134.4) | 68 (54.3 to 84.8) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for hemagglutination inhibition titers (B/Phuket) were reported in the descriptive data section of this outcome measure. GMR of NTs for hemagglutination inhibition titers (B/Phuket), calculated as ratio of GMTs of Group 7 to Group 5, was reported in the statistical analysis section.
| Titer | Group 7: RSVpreF + BNT162b2 + QIV | Group 5: QIV + Placebo |
|---|---|---|
| GMT and GMR of the Strain-Specific HAI Titers (B/Phuket) of QIV at 1 Month After Vaccination: Group 7 Versus Group 5 | 93 (78.5 to 111.0) | 27 (21.5 to 33.3) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV A were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV A, calculated as ratio of GMTs of Group 6 to Group 4, was reported in the statistical analysis section.
| Titer | Group 6: RSVpreF + BNT162b2 + Placebo | Group 4: RSVpreF + Placebo |
|---|---|---|
| GMT and GMR of NTs for RSV A at 1 Month After Vaccination: Group 6 Versus Group 4 | 26452 (22515.2 to 31076.8) | 18498 (15570.0 to 21975.9) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for RSV B were reported in the descriptive data section of this outcome measure. GMR of NTs for RSV B, calculated as ratio of GMTs of Group 6 to Group 4, was reported in the statistical analysis section.
| Titer | Group 6: RSVpreF + BNT162b2 + Placebo | Group 4: RSVpreF + Placebo |
|---|---|---|
| GMT and GMR of NTs for RSV B at 1 Month After Vaccination: Group 6 Versus Group 4 | 22859 (19040.4 to 27442.5) | 16677 (13884.0 to 20031.4) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 Omicron BA.4/BA.5 were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5, calculated as ratio of GMTs of Group 6 to Group 3, was reported in the statistical analysis section.
| Titer | Group 6: RSVpreF + BNT162b2 + Placebo | Group 3: BNT162b2 + Placebo |
|---|---|---|
| GMT and GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5 at 1 Month After Vaccination: Group 6 Versus Group 3 | 3430 (2756.9 to 4267.7) | 3667 (2861.9 to 4697.5) |
GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). GMTs of NTs for SARS-CoV-2 reference strain were reported in the descriptive data section of this outcome measure. GMR of NTs for SARS-CoV-2 reference strain calculated as ratio of GMTs of Group 6 to Group 3, was reported in the statistical analysis section.
| Titer | Group 6: RSVpreF + BNT162b2 + Placebo | Group 3: BNT162b2 + Placebo |
|---|---|---|
| GMT and GMR of NTs for SARS-CoV-2 Reference Strain at 1 Month After Vaccination: Group 6 Versus Group 3 | 12111 (10010.3 to 14652.1) | 12439 (10185.9 to 15190.1) |
Collected over Local reactions and systemic events: From Day 1 to Day 7 after Vaccination 1; Non serious AEs: up to 1 month after Vaccination 1, SAEs: up to 6 months after Vaccination 1. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: [RSVpreF + BNT162b2] + QIV | 0/154 (0%) | 1/154 (0.6%) | 114/154 (74%) |
| Group 2: [RSVpreF+BNT162b2] + Placebo | 0/153 (0%) | 2/153 (1.3%) | 107/153 (69.9%) |
| Group 3: BNT162b2 + Placebo | 0/150 (0%) | 4/150 (2.7%) | 110/150 (73.3%) |
| Group 4: RSVpreF + Placebo | 0/152 (0%) | 2/152 (1.3%) | 73/152 (48%) |
| Group 5: QIV + Placebo | 0/149 (0%) | 2/149 (1.3%) | 96/149 (64.4%) |
| Group 6: RSVpreF + BNT162b2 + Placebo | 0/157 (0%) | 1/157 (0.6%) | 114/157 (72.6%) |
| Group 7: RSVpreF + BNT162b2 + QIV | 0/158 (0%) | 3/158 (1.9%) | 122/158 (77.2%) |
| Event | Group 1: [RSVpreF + BNT162b2] + QIV | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo | Group 4: RSVpreF + Placebo | Group 5: QIV + Placebo | Group 6: RSVpreF + BNT162b2 + Placebo | Group 7: RSVpreF + BNT162b2 + QIV |
|---|---|---|---|---|---|---|---|
| Chest painGeneral disorders | 0/154 | 0/153 | 0/150 | 1/152 | 1/149 | 0/157 | 0/158 |
| Cerebellar ataxiaNervous system disorders | 0/154 | 0/153 | 0/150 | 0/152 | 1/149 | 0/157 | 0/158 |
| TremorNervous system disorders | 0/154 | 0/153 | 0/150 | 0/152 | 1/149 | 0/157 | 0/158 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/154 | 0/153 | 1/150 | 0/152 | 0/149 | 0/157 | 0/158 |
| Ischaemic strokeNervous system disorders | 0/154 | 0/153 | 1/150 | 0/152 | 0/149 | 0/157 | 0/158 |
| Thalamic strokeNervous system disorders | 0/154 | 0/153 | 1/150 | 0/152 | 0/149 | 0/157 | 0/158 |
| CystoceleReproductive system and breast disorders | 0/154 | 0/153 | 1/150 | 0/152 | 0/149 | 0/157 | 0/158 |
| RectoceleReproductive system and breast disorders | 0/154 | 0/153 | 1/150 | 0/152 | 0/149 | 0/157 | 0/158 |
| Vaginal prolapseReproductive system and breast disorders | 0/154 | 0/153 | 1/150 | 0/152 | 0/149 | 0/157 | 0/158 |
| Middle cerebral artery strokeNervous system disorders | 0/154 | 0/153 | 0/150 | 1/152 | 0/149 | 0/157 | 0/158 |
| Event | Group 1: [RSVpreF + BNT162b2] + QIV | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo | Group 4: RSVpreF + Placebo | Group 5: QIV + Placebo | Group 6: RSVpreF + BNT162b2 + Placebo | Group 7: RSVpreF + BNT162b2 + QIV |
|---|---|---|---|---|---|---|---|
| Injection site pain (PAIN AT THE INJECTION SITE)General disorders | 88/154 | 80/153 | 94/150 | 16/152 | 77/149 | 89/157 | 85/158 |
| Fatigue (FATIGUE)General disorders | 65/154 | 57/153 | 53/150 | 37/152 | 43/149 | 61/157 | 74/158 |
| Headache (HEADACHE)Nervous system disorders | 33/154 | 38/153 | 34/150 | 29/152 | 19/149 | 38/157 | 30/158 |
| Myalgia (NEW OR WORSENED MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 20/154 | 17/153 | 16/150 | 15/152 | 16/149 | 22/157 | 23/158 |
| Injection site erythema (REDNESS)General disorders | 12/154 | 14/153 | 11/150 | 4/152 | 6/149 | 20/157 | 14/158 |
| Injection site swelling (SWELLING)General disorders | 8/154 | 17/153 | 14/150 | 5/152 | 9/149 | 20/157 | 11/158 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 17/154 | 5/153 | 8/150 | 16/152 | 14/149 | 7/157 | 20/158 |
| Chills (CHILLS)General disorders | 16/154 | 12/153 | 14/150 | 6/152 | 3/149 | 16/157 | 17/158 |
| Arthralgia (NEW OR WORSENED JOINT PAIN)Musculoskeletal and connective tissue disorders | 13/154 | 11/153 | 13/150 | 9/152 | 6/149 | 16/157 | 15/158 |
| Pyrexia (FEVER)General disorders | 6/154 | 5/153 | 2/150 | 2/152 | 0/149 | 3/157 | 7/158 |
Safety population included all participants who received the study intervention.
| Age, Continuous(Years) | Group 1: [RSVpreF + BNT162b2] + QIV | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo | Group 4: RSVpreF + Placebo | Group 5: QIV + Placebo | Group 6: RSVpreF + BNT162b2 + Placebo | Group 7: RSVpreF + BNT162b2 + QIV | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 71.7 ± 5.36 | 71.7 ± 5.01 | 71.1 ± 4.70 | 72.1 ± 4.69 | 72.3 ± 5.12 | 71.3 ± 4.87 | 71.6 ± 4.79 | 71.7 ± 4.94 |
| Sex: Female, Male(Participants) | Group 1: [RSVpreF + BNT162b2] + QIV | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo | Group 4: RSVpreF + Placebo | Group 5: QIV + Placebo | Group 6: RSVpreF + BNT162b2 + Placebo | Group 7: RSVpreF + BNT162b2 + QIV | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 88 | 94 | 81 | 81 | 81 | 95 | 83 | 603 |
| Male | 67 | 60 | 71 | 74 | 70 | 63 | 75 | 480 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: [RSVpreF + BNT162b2] + QIV | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo | Group 4: RSVpreF + Placebo | Group 5: QIV + Placebo | Group 6: RSVpreF + BNT162b2 + Placebo | Group 7: RSVpreF + BNT162b2 + QIV | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 21 | 15 | 11 | 18 | 12 | 18 | 15 | 110 |
| Not Hispanic or Latino | 134 | 138 | 140 | 137 | 139 | 139 | 142 | 969 |
| Unknown or Not Reported | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 4 |
| Race (NIH/OMB)(Participants) | Group 1: [RSVpreF + BNT162b2] + QIV | Group 2: [RSVpreF+BNT162b2] + Placebo | Group 3: BNT162b2 + Placebo | Group 4: RSVpreF + Placebo | Group 5: QIV + Placebo | Group 6: RSVpreF + BNT162b2 + Placebo | Group 7: RSVpreF + BNT162b2 + QIV | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 4 |
| Asian | 8 | 4 | 2 | 1 | 3 | 3 | 5 | 26 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 10 | 12 | 13 | 10 | 9 | 14 | 13 | 81 |
| White | 135 | 138 | 133 | 143 | 136 | 140 | 138 | 963 |
| More than one race | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 2 | 1 | 1 | 0 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2023 to primary completion in Jan 2024, 6 months.
Results were first posted in Dec 2024, 11 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 6 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrysvo